Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation
- 19 January 2013
- journal article
- research article
- Published by Elsevier BV in Health Policy
- Vol. 109 (3), 263-269
- https://doi.org/10.1016/j.healthpol.2012.12.005
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- From evidence assessments to coverage decisions? The case example of glinides in GermanyHealth Policy, 2012
- Wohlfahrt oder wohlfeil?Der Onkologe, 2011
- Pharmaceutical Pricing and Reimbursement Policies in GermanySSRN Electronic Journal, 2008
- Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysisHealth Policy, 2007
- Physician Drug Budgets in Germany and Effects on Prescription BehaviourJournal of Pharmaceutical Finance, Economics & Policy, 2006
- Impact of Cross-Reference Pricing on Pharmaceutical PricesApplied Health Economics and Health Policy, 2006
- Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?The International Journal of Health Planning and Management, 2005
- Examining the link between price regulation and pharmaceutical R&D investmentHealth Economics, 2004
- The Link Between Gross Profitability And Pharmaceutical R&D SpendingHealth Affairs, 2001
- The role of economic evaluation in the pricing and reimbursement of medicinesHealth Policy, 1997